作者: 朦朧 時(shí)間: 2025-3-22 00:18
Pathophysiology of Heart Failureologies can be responsible for HF, including but not limited to ischemic heart disease, valvular heart disease, infiltrative disease, restrictive physiology, genetic conditions, and idiopathic cardiomyopathy. The cardinal manifestations are dyspnea and fatigue. The syndrome of HF is a continuum of i作者: 阻擋 時(shí)間: 2025-3-22 04:10 作者: 食料 時(shí)間: 2025-3-22 08:23 作者: 責(zé)怪 時(shí)間: 2025-3-22 12:32
Extracorporeal Membrane Oxygenationand provides temporary support for patients with cardiac and pulmonary failure. Because of the ease of institution, ECMO can be started emergently and can provide almost immediate cardiopulmonary support for patients in hemodynamically unstable clinical conditions. Though ECMO and extracorporeal lif作者: homeostasis 時(shí)間: 2025-3-22 16:53
Ventricular Assist Device as Bridge-to-Transplanttion is increasing. With the development of the continuous flow device, there has been improved mechanical durability with a resultant decrease in waitlist mortality for patient who are waiting for heart transplantation. When selecting patients for potential assist device therapy, it is important to作者: homeostasis 時(shí)間: 2025-3-22 18:11
Current Listing Systemed States. In 2016, a 10-year update to the 2006 International Listing Criteria for Heart Transplantation was published by the International Society for Heart and Lung Transplantation (ISHLT). Criteria were revised to reflect advances in the management of advanced heart failure patients, incorporate作者: 橡子 時(shí)間: 2025-3-23 00:51
Recent Changes and Future Challenges in the Heart Allocation Systemuires the integration of objective data, clinical intuition, and moral fairness. Institution of an allocation system by UNOS has provided important structure to the allocation methodology. The system must be periodically reviewed and reorganized to ensure it is reflective of current patient disease 作者: 飛鏢 時(shí)間: 2025-3-23 03:50 作者: 妨礙議事 時(shí)間: 2025-3-23 08:36 作者: 我還要背著他 時(shí)間: 2025-3-23 12:33
Ex Vivo Perfusionrain on heart transplant programs around the world. Efforts to increase the number of available donors with increased organ sharing and donor recruitment and use of extended criteria donors have had only modest effect at supplying needed organs. Because of these challenges, there has been a revival 作者: 多骨 時(shí)間: 2025-3-23 17:31 作者: 課程 時(shí)間: 2025-3-23 20:12
2570-1592 chnologies and future possibilities.This work provides a one-of- a-kind volume that includes all aspects of heart transplantation from its historic beginning to its current day standards which now make the procedure a long-term treatment option for heart failure patients. ?The subjects covered inclu作者: eczema 時(shí)間: 2025-3-23 22:23
Explanations, Identities, and Theories,tlist mortality for patient who are waiting for heart transplantation. When selecting patients for potential assist device therapy, it is important to consider heart failure severity for timing of device implantation, right ventricular function, and ability to tolerate anticoagulation.作者: 浸軟 時(shí)間: 2025-3-24 03:32 作者: 格子架 時(shí)間: 2025-3-24 07:44
Ventricular Assist Device as Bridge-to-Transplanttlist mortality for patient who are waiting for heart transplantation. When selecting patients for potential assist device therapy, it is important to consider heart failure severity for timing of device implantation, right ventricular function, and ability to tolerate anticoagulation.作者: 美麗的寫 時(shí)間: 2025-3-24 13:46
https://doi.org/10.1007/978-94-010-0786-3imension of organ supply and demand. The current trend of using marginal donors for higher-risk patients solves part of this ethical dilemma. As such, the contraindications discussed must be viewed in this broader context and may at times be dynamic.作者: 防止 時(shí)間: 2025-3-24 17:44 作者: Arresting 時(shí)間: 2025-3-24 22:35 作者: 衣服 時(shí)間: 2025-3-24 23:56
Extracorporeal Membrane Oxygenationluded discussion on the historical inception of ECMO, expansion in scope, the indications, and clinical conditions it is used for and its role as a bridge to heart and lung transplantation in selected patients.作者: ALIEN 時(shí)間: 2025-3-25 05:55
Recent Changes and Future Challenges in the Heart Allocation Systemy candidates. To address these changes, UNOS Thoracic Organ Transplantation Committee was tasked with providing a revised allocation system. The resulting system aims to improve waitlist mortality and posttransplant outcomes by better prioritizing the highest acuity patients while improving the geographic distribution of organ offers.作者: 改良 時(shí)間: 2025-3-25 09:01 作者: 嚴(yán)峻考驗(yàn) 時(shí)間: 2025-3-25 14:05
https://doi.org/10.1007/978-94-010-3293-3ce organ procurement and to therapeutically intervene to improve organ quality. From early conceptual beginnings to the future potential of the therapy, this manuscript covers the evolution of ex vivo machine perfusion for support of heart transplantation.作者: BLANC 時(shí)間: 2025-3-25 16:54
Ex Vivo Perfusionce organ procurement and to therapeutically intervene to improve organ quality. From early conceptual beginnings to the future potential of the therapy, this manuscript covers the evolution of ex vivo machine perfusion for support of heart transplantation.作者: Metamorphosis 時(shí)間: 2025-3-25 22:32 作者: figment 時(shí)間: 2025-3-26 01:24 作者: 連接 時(shí)間: 2025-3-26 04:28 作者: PON 時(shí)間: 2025-3-26 10:37
Contemporary Heart Transplantation978-3-319-58054-8Series ISSN 2570-1592 Series E-ISSN 2570-1606 作者: Pathogen 時(shí)間: 2025-3-26 14:37 作者: Creatinine-Test 時(shí)間: 2025-3-26 18:16
Organ and Tissue Transplantationhttp://image.papertrans.cn/c/image/236498.jpg作者: Anthem 時(shí)間: 2025-3-26 23:33 作者: gerontocracy 時(shí)間: 2025-3-27 03:05 作者: BADGE 時(shí)間: 2025-3-27 06:15
https://doi.org/10.1007/978-94-010-0786-3contraindications may be less absolute and more flexible than initially proposed. When assessing whether a certain patient-related factor is prohibitive, the stagnant donor pool should be taken into consideration. We must remain an advocate for the individual patient while factoring in the ethical d作者: contradict 時(shí)間: 2025-3-27 12:19 作者: municipality 時(shí)間: 2025-3-27 15:25
https://doi.org/10.1007/978-94-010-1188-4and provides temporary support for patients with cardiac and pulmonary failure. Because of the ease of institution, ECMO can be started emergently and can provide almost immediate cardiopulmonary support for patients in hemodynamically unstable clinical conditions. Though ECMO and extracorporeal lif作者: circumvent 時(shí)間: 2025-3-27 18:22
Explanations, Identities, and Theories,tion is increasing. With the development of the continuous flow device, there has been improved mechanical durability with a resultant decrease in waitlist mortality for patient who are waiting for heart transplantation. When selecting patients for potential assist device therapy, it is important to作者: 顯而易見(jiàn) 時(shí)間: 2025-3-28 00:46
Stability in ecosystems: some commentsed States. In 2016, a 10-year update to the 2006 International Listing Criteria for Heart Transplantation was published by the International Society for Heart and Lung Transplantation (ISHLT). Criteria were revised to reflect advances in the management of advanced heart failure patients, incorporate作者: 可卡 時(shí)間: 2025-3-28 02:36 作者: 好開(kāi)玩笑 時(shí)間: 2025-3-28 08:16 作者: 拱墻 時(shí)間: 2025-3-28 10:33
W. H. Dobben,R. H. Lowe-McConnellsplant, major advances have occurred in the field of heart transplantation, including new surgical strategies. There continues to be an increasing donor shortage for patients on the heart transplant waiting list. Providers need to fully understand the process of retrieving a heart from a donor and a作者: 纖細(xì) 時(shí)間: 2025-3-28 18:31 作者: capsule 時(shí)間: 2025-3-28 18:47
A. J. M. Watson,M. J. G. Farthingry or even years following transplantation. An increasing number of patients are at risk of surgical injuries and bleeding complications as more patients are currently being bridged to transplantation with durable mechanical support devices and therefore have a history of prior sternotomies and are 作者: 牽連 時(shí)間: 2025-3-29 00:10
https://doi.org/10.1007/978-94-010-0057-4an Shumway pioneered the use of a calcineurin inhibitor, cyclosporine as a more potent immunosuppressive agent to mitigate rejection after cardiac transplantation. With the successful incorporation of cyclosporine, short and intermediate-term survival improved dramatically and between 1980 and 1990,作者: Expurgate 時(shí)間: 2025-3-29 05:47 作者: 平 時(shí)間: 2025-3-29 09:37
Physical Behavior of Aerosol Particles, cardiac landscape. Social workers in cardiac transplant have been called upon to acquire different skill sets to incorporate the cataclysmic changes in cardiac care. Developing a psychosocial assessment tool is the foundation of performing a comprehensive, thorough, and detailed evaluation of the t作者: 正常 時(shí)間: 2025-3-29 15:07
Stability in ecosystems: some commentsioritization of higher-status patients within larger geographic areas, lower suggested cutoff values for minimal estimated glomerular filtration rate, assessment of the adequacy of social support in potential transplant candidates, and the role of heart failure prognosis scores in ambulatory patient作者: 不要嚴(yán)酷 時(shí)間: 2025-3-29 19:22 作者: Pcos971 時(shí)間: 2025-3-29 22:55 作者: Schlemms-Canal 時(shí)間: 2025-3-30 02:15
A. J. M. Watson,M. J. G. Farthingrs, and pulmonary vasodilators, many patients require temporary mechanical support to rest the heart and allow graft recovery. Other less common acute and chronic complications are also discussed in this chapter including aortic complications, heart oversizing, wound infections, pericardial effusion作者: 的’ 時(shí)間: 2025-3-30 06:22
History of Heart Transplantan Shumway pioneered the use of a calcineurin inhibitor, cyclosporine as a more potent immunosuppressive agent to mitigate rejection after cardiac transplantation. With the successful incorporation of cyclosporine, short and intermediate-term survival improved dramatically and between 1980 and 1990,
